Temsirolimus: in advanced renal cell carcinoma

Related Experiment Video

Updated: Jul 6, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Dene Simpson1, Monique P Curran

  • 1Wolters Kluwer Health, Adis, Auckland, New Zealand. demail@adis.co.nz

Drugs
|March 29, 2008
PubMed

Insights

Temsirolimus significantly improved survival for advanced renal cell carcinoma patients compared to interferon-alpha. This mTOR inhibitor demonstrated better progression-free survival and fewer adverse events.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Advanced renal cell carcinoma (RCC) presents a poor prognosis.
  • Current therapies like interferon-alpha (IFNalpha) have limitations.
  • Targeting the mammalian target of rapamycin (mTOR) pathway is a therapeutic strategy.

Purpose of the Study:

  • To evaluate the efficacy and safety of temsirolimus in patients with advanced RCC.
  • To compare temsirolimus monotherapy against standard IFNalpha treatment.

Main Methods:

  • A large phase III clinical study was conducted.
  • Patients received either a once-weekly intravenous infusion of temsirolimus (25 mg) or subcutaneous IFNalpha (3-18 MU three times weekly).
  • Survival outcomes, objective response rates, and adverse events were assessed.

Main Results:

  • Temsirolimus showed significant survival benefits: median overall survival of 10.9 months vs. 7.3 months for IFNalpha.
  • Progression-free survival was notably improved with temsirolimus (5.5 months vs. 3.1 months).
  • Objective response rates were higher for temsirolimus (8.6%) than IFNalpha (4.8%), with fewer severe adverse events.

Conclusions:

  • Temsirolimus monotherapy offers significant survival advantages for advanced RCC patients with poor prognosis.
  • Temsirolimus is a well-tolerated treatment option with a favorable safety profile compared to IFNalpha.
  • Targeting the mTOR pathway with temsirolimus is an effective strategy in advanced renal cell carcinoma treatment.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...